Mick Whitley
Main Page: Mick Whitley (Labour - Birkenhead)Department Debates - View all Mick Whitley's debates with the Department of Health and Social Care
(3 years, 6 months ago)
Commons ChamberRead Full debate Read Hansard Text Watch Debate Read Debate Ministerial Extracts
Urgent Questions are proposed each morning by backbench MPs, and up to two may be selected each day by the Speaker. Chosen Urgent Questions are announced 30 minutes before Parliament sits each day.
Each Urgent Question requires a Government Minister to give a response on the debate topic.
This information is provided by Parallel Parliament and does not comprise part of the offical record
Nadhim Zahawi
I will certainly take my right hon. Friend’s constituents’ details and look into that. We urge all hospitals to make sure that when the frail elderly need social contact, they are able to get it.
Mick Whitley (Birkenhead) (Lab) [V]
No one is safe from covid-19 until we all are, but the UK continues to stubbornly resist calls for a waiver of covid-19 vaccine patents. Given that people in many of the world’s poorest countries cannot expect to be vaccinated until 2023, and given the failure of the COVAX initiative to distribute vaccines at the volume and speed that is needed, will the Government now follow the lead of the Biden Administration and reverse their position on a patent waiver?
Nadhim Zahawi
That is a really important question. Let me share with the hon. Member a little about the operational challenges around vaccine manufacture. We will of course look at any text that our US colleagues put forward on the intellectual property issue, but in reality if the exam question is to get more jabs in the arms of those who live in low and middle-income countries, the bottleneck is not the IP but the transfer of technology to manufacturers around the world. What Oxford-AstraZeneca has done incredibly well is to transfer that technology to 20 sites that can manufacture at scale. We have already delivered 450 million doses of the Oxford-AstraZeneca vaccine. The hon. Gentleman might recall that Pfizer did the same thing; it actually paused its manufacturing in Europe and expanded it, to go from 1.2 billion doses a year for 2021 to almost 3 billion doses. If the exam question is to get more jabs in arms, we need that technology transfer. It is not easy, as we saw in Halix in Europe, which had great difficulty operationalising the manufacturing, as did Catalent in the US. That is the real effort that needs to go in—as well, of course, as helping other countries with deployment. It is only one part of the jigsaw to get the vaccine into warehouses in those countries; those countries have to be able to get it out and into people’s arms.